2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

2013 Symposium Photos

2012 Featured Talks

2012 Symposium Photos

2011 Featured Talks

2011 Symposium Photos

Past Symposia in the Press

2013 Featured Talks » Translational Oncology activity of Kyowa Kirin, Discovery and development of CCR4 monoclonal antibody, mogamulizumab

Translational Oncology activity of Kyowa Kirin, Discovery and development of CCR4 monoclonal antibody, mogamulizumab

Yukimasa Shiotsu, PhD, was appointed Director of Translational Oncology for Kyowa Hakko Kirin California in January 2013. He has more than 15 years experience in oncology research/development and has managed several research and development projects for Kyowa Hakko Kogyo Co. and Kyowa Hakko Kirin Co (KHK). He began working for Kyowa Hakko KogyoCo. in 1991, as a research scientist in its Tokyo Research Laboratories and later moved to its Pharmaceutical Research Institute. In July 1999, he moved to the Oncology Group, where he worked as a research scientist and research planner. He managed the Department of Oncology for three years, before becoming manager of the Department of Non-clinical Development and later the Department of Strategy Planning in the company’s Pharmaceutical Research Center. After the company’s merger with Kirin Pharma, Shiotsu worked in the research division as group head of the drug discovery lab and later was deputy director of its bio medical lab.

Shiotsu is a board member of Japanese Association of Metastasis Cancer Research and is member of the Japanese Association for Cancer Research, the Japanese Association for Molecular Target Therapy of Cancer, the American Association of Cancer Research and the American Society of Hematology. He is widely published with more than 35 articles in major journals. He was a visiting scientist at the University of British Columbia Graduate School and earned a Ph.D. in Agricultural/Life Science from the University of Tokyo in 2000.